KYTX
NASDAQ · Biotechnology
Kyverna Therapeutics Inc
$8.67
+0.05 (+0.58%)
Open$8.66
Previous Close$8.62
Day High$8.76
Day Low$8.51
52W High$13.67
52W Low$2.52
Volume—
Avg Volume720.1K
Market Cap490.62M
P/E Ratio—
EPS$-3.28
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-5.9% upside
Current
$8.67
$8.67
Target
$8.16
$8.16
$5.68
$8.16 avg
$10.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |
| Rev Growth | +5.4% | +22.1% | -7.0% |
| Debt/Equity | 0.25 | 0.20 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |